亿胜生物(01061.HK)参展亚太眼科学会年会报告贝伐珠单抗候选药物临床数据

阿斯达克财经

02/10

亿胜生物(01061.HK) 公布，成功参展于2026年2月5日至8日在香港会议展览中心举办的第41届亚太眼科学会年会(APAO 2026)。公司的海报研究《贝伐珠单抗与雷珠单抗治疗湿性年龄相关性黄斑变性的解剖学及患者报告结局：AURA-1研究》获选大会口头报告。该报告基于贝伐珠单抗候选药物(EB12-20145P)的III期临床数据，重点阐述了集团在湿性年龄相关性黄斑变性(wAMD)抗血管内皮...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610643573"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610643573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610643573?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230517145836273_s.jpg","is_english":false,"pubTime":"2026-02-10 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610643573","market":"fut","top_or_hot":-1,"title":"亿胜生物(01061.HK)参展亚太眼科学会年会 报告贝伐珠单抗候选药物临床数据","media":"阿斯达克财经","content":"<div>\n<p>亿胜生物(01061.HK) 公布，成功参展于2026年2月5日至8日在香港会议展览中心举办的第41届亚太眼科学会年会(APAO 2026)。公司的海报研究《贝伐珠单抗与雷珠单抗治疗湿性年龄相关性黄斑变性的解剖学及患者报告结局：AURA-1研究》获选大会口头报告。该报告基于贝伐珠单抗候选药物(EB12-20145P)的III期临床数据，重点阐述了集团在湿性年龄相关性黄斑变性(wAMD)抗血管内皮...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亿胜生物(01061.HK)参展亚太眼科学会年会 报告贝伐珠单抗候选药物临床数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亿胜生物(01061.HK)参展亚太眼科学会年会 报告贝伐珠单抗候选药物临床数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 17:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>亿胜生物(01061.HK) 公布，成功参展于2026年2月5日至8日在香港会议展览中心举办的第41届亚太眼科学会年会(APAO 2026)。公司的海报研究《贝伐珠单抗与雷珠单抗治疗湿性年龄相关性黄斑变性的解剖学及患者报告结局：AURA-1研究》获选大会口头报告。该报告基于贝伐珠单抗候选药物(EB12-20145P)的III期临床数据，重点阐述了集团在湿性年龄相关性黄斑变性(wAMD)抗血管内皮...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN","article_id":"2610643573","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230517145836273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610643573","pubTimestamp":1770716040,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"亿胜生物(01061.HK) 公布，成功参展于2026年2月5日至8日在香港会议展览中心举办的第41届亚太眼科学会年会(APAO 2026)。公司的海报研究《贝伐珠单抗与雷珠单抗治疗湿性年龄相关性黄斑变性的解剖学及患者报告结局：AURA-1研究》获选大会口头报告。该报告基于贝伐珠单抗候选药物(EB12-20145P)的III期临床数据，重点阐述了集团在湿性年龄相关性黄斑变性(wAMD)抗血管内皮生长因子(anti-VEGF)疗法领域持续取得的临床进展。(ss/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-10 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01061":"亿胜生物科技","BK1161":"生物科技"},"translate_title":"Essex Biologics (01061. HK) participated in the annual meeting of the Asia-Pacific Society of Ophthalmology to report the clinical data of bevacizumab drug candidates","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1.5},"content_text":"亿胜生物(01061.HK) 公布，成功参展于2026年2月5日至8日在香港会议展览中心举办的第41届亚太眼科学会年会(APAO 2026)。公司的海报研究《贝伐珠单抗与雷珠单抗治疗湿性年龄相关性黄斑变性的解剖学及患者报告结局：AURA-1研究》获选大会口头报告。该报告基于贝伐珠单抗候选药物(EB12-20145P)的III期临床数据，重点阐述了集团在湿性年龄相关性黄斑变性(wAMD)抗血管内皮生长因子(anti-VEGF)疗法领域持续取得的临床进展。(ss/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-10 16:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}

亿胜生物(01061.HK)参展亚太眼科学会年会 报告贝伐珠单抗候选药物临床数据

热议股票

亿胜生物(01061.HK)参展亚太眼科学会年会报告贝伐珠单抗候选药物临床数据